DAVID CELLA received the National Academy of Medicine Gustav O. Lienhard Award, which recognizes his pioneering work in measuring and applying patient reported outcomes in healh care. The award consists of a medal and $40,000. Cella is the Ralph Seal Paffenbarger Professor and chair, department of medical social sciences, and director, Center for Patient-Centered Outcomes,...
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
